Non Small Cell Lung CancerLymph Node MetastasisPositron Emission Tomography
Study summary
This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.
Eligibility
Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
* Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
* Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
* No prior radiotherapy or chemotherapy for initial treatment.
* No history of malignant tumors.
Exclusion Criteria:
* Locally advanced or distant metastasis.
* Pleural dissemination observed during surgery.
* History of malignant tumors.
* Received neoadjuvant therapy.
* Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).
Primary outcome measure(s)
Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis — from enrollment to 1 month after surgery
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.